6/9 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
et al., medRxix, doi:10.1101/2020.06.09.20116806 (Preprint)
Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers
Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers
HCQ reduced cases from 38% to 7%. 106 people. No serious adverse effects.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Bhattacharya et al., 6/9/2020, retrospective, India, South Asia, preprint, 7 authors.
risk of COVID-19 case, 80.7% lower, RR 0.19, p = 0.001, treatment 4 of 54 (7.4%), control 20 of 52 (38.5%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC.